Antitrust - Amarin Pharma - Dr. Reddy's litigation over alleged delay of generic Vascepa (US)

Track this case file

Amarin Pharma has been accused of illegally delaying generic competition for the branded cardiovascular drug Vascepa. Dr. Reddy’s Laboratories claims that Amarin used exclusivity agreements to prevent any suppliers of a necessary active ingredient with sufficient capacity from supporting a commercial launch in a timely manner. According to the complaint, without Amarin’s interference, DRL would have been able to manufacture a competing generic after winning two patent cases against Amarin.

To add details to this portfolio regarding legal or economic representatives, please contact editors@mlex.com

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login